Cell & Gene Exchange, May 2017: MEDIPOST America
MEDIPOST develops allogeneic stem cell products using multi-potent human Umbilical Cord Blood-derived Mesenchymal Stem Cells (hUCB-MSCs). MEDIPOST also operates the largest Cord Blood Bank – CellTree™, in Korea with over 220,000 units of cord blood stored covering over 45% of private cord blood banking market-share in Korea. MEDIPOST America Inc. is a wholly-owned US subsidiary.
MEDIPOST has introduced the world's first allogeneic off-the-shelf hUCB-MSC product – CARTISTEM®, into the Korean market approved by the Ministry of Food and Drug Safety (formerly Korea FDA) for patients with knee osteoarthritis (OA) across all ages. CARTISTEM® completed Phase I/II and III clinical trials in Korea leading to market-approval in 2012. CARTISTEM® also completed Phase I/II clinical trial in the US. MEDIPOST’s other pipeline of allogeneic hUCB-MSC products target Broncho-pulmonary Dysplasia (BPD) in premature infants (Phase I and II complete in Korea; Phase I/II complete in the US) and Alzheimer’s disease (Phase I complete in Korea).
Speaker: Antonio Lee – CEO